Spots Global Cancer Trial Database for mek162
Every month we try and update this database with for mek162 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer | NCT02276027 | Adenocarcinoma ... | BYL719 INC280 LDK378 MEK162 | 18 Years - | Novartis | |
| A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | NCT01801358 | Uveal Melanoma | AEB071 MEK162 | 18 Years - | Array BioPharma | |
| A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | NCT03158103 | Gastrointestina... | MEK162 Pexidartinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors | NCT01469130 | Advanced Solid ... | MEK162 | 18 Years - | Array BioPharma | |
| A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | NCT03158103 | Gastrointestina... | MEK162 Pexidartinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Sequential Combo Immuno and Target Therapy (SECOMBIT) Study | NCT02631447 | Metastatic Mela... | LGX818 MEK162 Nivolumab Ipilimumab | 18 Years - | Fondazione Melanoma Onlus | |
| Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant | NCT04322383 | Hairy Cell Leuk... | binimetinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma | NCT02159066 | Melanoma | LGX818 MEK162 LEE011 BGJ398 BKM120 INC280 | 18 Years - | Pfizer | |
| A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors | NCT01543698 | Solid Tumors Ha... | LGX818 MEK162 LEE011 | 18 Years - | Pfizer | |
| MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | NCT01991379 | Gastrointestina... | MEK162 Imatinib Mesyla... Blood draws biopsy | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | NCT04324112 | Hairy Cell Leuk... | binimetinib Encorafenib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma | NCT01763164 | Metastatic or U... | MEK162 Dacarbazine | 18 Years - | Pfizer | |
| A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma | NCT01320085 | BRAF or NRAS Mu... | MEK162 | 18 Years - | Pfizer | |
| A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation | NCT01859026 | Lung Cancer Non-Small Cell ... | MEK162 Erlotinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | NCT01562899 | Metastatic Panc... BRAF Mutated Me... | MEK162 AMG 479 | 18 Years - | Pfizer | |
| A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma | NCT01781572 | Locally Advance... | LEE011 MEK162 | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
